Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EMB-07 |
Synonyms | |
Therapy Description |
EMB-07 is a bispecific T-cell engager that targets ROR1 expressed on tumor cells and CD3, which potentially induces killing of tumor cells expressing ROR1 and leads to inhibition of tumor growth (Cancer Res (2024) 84 (7_Supplement): LB126). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EMB-07 | EMB 07|EMB07 | CD3 Antibody 99 ROR1 Antibody 7 | EMB-07 is a bispecific T-cell engager that targets ROR1 expressed on tumor cells and CD3, which potentially induces killing of tumor cells expressing ROR1 and leads to inhibition of tumor growth (Cancer Res (2024) 84 (7_Supplement): LB126). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | AUS | 1 |